Showing results 1 to 1 of 1
| Title | Author(s) | Issue Date | |
|---|---|---|---|
LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatinib (L) Proceeding/Conference:Journal of Clinical Oncology | 2012 |